Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Completed

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).

Key facts

Study ID

NCT06500741

Run by

Astellas Pharma Global Development, Inc.

People needed

374

Starts

2024-11-22

Expected to finish

2025-04-02

Last updated by the study team

2025-05-06

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Physician inclusion criteria
• The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
• The physician has cared for at least ten nmHSPC patients in the past year.
• The physician has experience prescribing NHT and ADT. Patient inclusion criteria
• The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.

You may not qualify if…

• Physician exclusion criteria
• None Patient exclusion criteria
• The patient is castration resistant.
• The patient has metastatic PC.

Where it is running

• Analysis Group, Inc. — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.